Gene therapy · developed by Neurocrine Biosciences
VY-AADC01 is a gene therapy delivered by neurosurgical infusion bilaterally into the striatum. It is studied in Parkinson's disease, a neurodegenerative movement disorder of the basal ganglia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03065192 | Phase 1 | Idiopathic Parkinson's Disease | Completed | VYGR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Basal Ganglia DiseaseBrain DiseasesCentral Nervous System DiseasesIdiopathic Parkinson's DiseaseMovement DisordersNervous System DiseasesNeurodegenerative DiseasesParkinson's DiseaseParkinsonian Disorders